Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00581607 · ClinicalTrials.gov registry record · Phase 2
Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension
A Phase 2 study, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 2
- Development phase
- 43
- Enrollment target
NCT00581607 is a Phase 2 study that has completed, run by University of Cincinnati. The registered enrollment target is 43 participants.
The verdict
NCT00581607, a Phase 2 study, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 43 participants
- Enrollment target
Study Summary
Patients with advanced sarcoidosis often develop pulmonary hypertension. Pulmonary hypertension is a condition where the right side of the heart has to push the blood though the lungs at a higher pressure than normal. Since this pressure is higher, it is harder for the heart to pump the blood through the lungs to the left side of the body. If the blood can not get through the lungs, it can not get pumped through the rest of the body. This leads to weakness and shortness of breath. This type of hypertension does not usually respond to regular blood pressure medicines. The purpose of this study is to determine if bosentan (Tracleer) will help sarcoidosis associated pulmonary hypertension.
Interventions
- DRUG Placebo
- DRUG Bosentan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2008-04 |
| Est. Completion | 2012-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00581607
The ClinicalTrials.gov registry entry for NCT00581607 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 43 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Cincinnati, which has 245 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00581607 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00581607 about?
NCT00581607 is a clinical study titled "Double Blind, Randomized Trial of Bosentan for Sarcoidosis Associated Pulmonary Hypertension". Patients with advanced sarcoidosis often develop pulmonary hypertension. Pulmonary hypertension is a condition where the right side of the heart has to push the blood though the lungs at a higher pressure than normal. Since this pressure is higher, it is harder for the heart to pump the blood throug...
What is the current status of trial NCT00581607?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 43 participants. The study started on 2008-04. Estimated completion is 2012-12.
What interventions are being tested in trial NCT00581607?
The interventions under investigation include: Placebo (DRUG), Bosentan (DRUG).
Who is sponsoring clinical trial NCT00581607?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.